694-43-9

Basic information

• Product Name: CIS-BICYCLO[3.1.0]HEXAN-3-OL
• Synonyms: CIS-BICYCLO[3.1.0]HEXAN-3-OL;(1R,3r,5S)-Bicyclo[3.1.0]hexan-3-ol;(1R,5S)-Bicyclo[3.1.0]hexan-3-ol;Cis-(1R,3r,5S)-bicyclo[3.1.0]hexan-3-ol
• CAS NO: 694-43-9
• Molecular Formula: C₆H₁₀O
• Molecular Weight: 98.143
• Mol File: 694-43-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 170.5±8.0 °C(Predicted)
• Appearance: /
• Density: 1.161±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 15.31±0.20(Predicted)
• CAS DataBase Reference: CIS-BICYCLO[3.1.0]HEXAN-3-OL(CAS DataBase Reference)
• NIST Chemistry Reference: CIS-BICYCLO[3.1.0]HEXAN-3-OL(694-43-9)
• EPA Substance Registry System: CIS-BICYCLO[3.1.0]HEXAN-3-OL(694-43-9)

Safety Data

• Hazardous Substances Data: 694-43-9(Hazardous Substances Data)

Usage

General Description

CIS-BICYCLO[3.1.0]HEXAN-3-OL is a chemical compound with a bicyclic structure and a hydroxyl group at the third carbon position. It is used in the synthesis of pharmaceuticals and organic compounds and has potential applications in the fragrance and flavor industries. The compound is known for its unique structure, which makes it suitable for use as a chiral building block in asymmetric synthesis. It is also known for its mild, citrus-like odor, which makes it a valuable ingredient in fragrance formulations. CIS-BICYCLO[3.1.0]HEXAN-3-OL has potential uses in various industries and continues to be the subject of research for its diverse applications.

Upstream product

• 75-11-6 diiodomethane 
• 14320-38-8 cyclopent-3-enol 
• 285-58-5 bicyclo<3.1.0>hexane 
• 1755-04-0 bicyclo[3.1.0]hexan-3-one 

Downstream Products

• 1755-04-0 bicyclo[3.1.0]hexan-3-one 
• 1284249-22-4 (trans)-bicyclo[3.1.0]hex-3-ylamine hydrochloride 
• 79531-79-6 trans-3-Amino-bicyclo<3,1,0>hexan 
• 1098189-15-1 vedroprevir 
• 1098189-07-1 C₃₁H₄₂BrN₃O₉S 
• 1365170-20-2 C₁₂H₁₄N₄O₂S 

Relevant articles and documents

OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE

The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity)

OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE

The present invention relates to a pharmaceutical technology, and more specifically, to optically pure benzyl-4-chloro-phenyl glucoside derivatives represented by the chemical formula II and III or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the compounds and intermediates thereof, pharmaceutical formulations and pharmaceutical compositions containing the compounds, and the use of the optically pure benzyl-4-chloro-phenyl glucoside derivatives as sodium glucose co-transporter (SGLT) inhibitors for the prevention and treatment of the diabetes including the insulin dependent diabetes mellitus and non-insulin dependent diabetes mellitus and the diabetes-related deseases such as insulin-resistant diseases and obesity.COPYRIGHT KIPO 2015

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.